Summary by Futu AI
JD Health announced its mid-year performance as of June 30, 2024, and appointed Professor Liao Jiajie as an independent non-executive director. The mid-year performance showed that the company's revenue reached 28.3 billion yuan, a year-on-year growth of 4.6%; gross profit reached 6.7 billion yuan, a year-on-year growth of 8.0%; operating profit reached 1.035 billion yuan, a year-on-year growth of 17.7%; pre-tax profit reached 2.439 billion yuan, a year-on-year growth of 33.2%; profit for the period reached 2.034 billion yuan, a year-on-year growth of 30.2%; and non-IFRS profit for the period reached 2.644 billion yuan, a year-on-year growth of 8.5%. The company continues to innovate in digital health services and strengthen its supply chain capabilities for medicine and health products. In addition, the company actively responds to national policies and promotes the development of digital healthcare services. Professor Liao Jiajie's appointment will take effect from August 15, 2024, and his extensive experience in the medical field will bring a new perspective to the company.